Table 2.
HRs of PFS events, n=88
| Cases/1000 person-years | Rate (per 1000 person-years) | HR | 95% CI | p Value | |
| LMR | |||||
| >3.20 | 11 | 34.66 | 0.34 | 0.16 to 0.74 | 0.004 |
| ≤3.20 | 16 | 101.28 | 1 | ||
| NLR | |||||
| >2.18 | 18 | 67.37 | 1.56 | 0.70 to 3.47 | 0.273 |
| ≤2.18 | 9 | 43.23 | 1 | ||
| FLIPI | |||||
| High risk | 19 | 82.30 | 2.52 | 1.10 to 5.75 | 0.023 |
| Low/intermediate risk | 8 | 32.72 | 1 | ||
| Sex | |||||
| Male | 15 | 58.96 | 1.09 | 0.51 to 2.32 | 0.831 |
| Female | 12 | 54.29 | 1 | ||
| Rituximab | |||||
| Yes | 4 | 22.02 | 0.28 | 0.10 to 0.81 | 0.012 |
| No | 23 | 78.31 | 1 | ||
| Year of diagnosis | |||||
| 2010–2014 | 1 | 8.71 | 0.10 | 0.01 to 0.75 | 0.006 |
| 2006–2010 | 5 | 43.05 | 0.50 | 0.19 to 1.33 | 0.157 |
| 2000–2005 | 21 | 85.91 | 1 | ||
FLIPI, Follicular Lymphoma International Prognostic Index; LMR, lymphocyte-to-monocyte ratio; NLR neutrophil-to-lymphocyte ratio; PFS, progression-free survival.